Reference number	
2438-H	

# SPECIALTY QUANTITY LIMIT PROGRAM

## Tagrisso (osimertinib)

#### I. PROGRAM DESCRIPTION

The initial limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization

#### II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Tagrisso 40 mg tablets	30 per 30 days	None	Standard dosing: 80 mg per day
			Severe toxicities, QTc interval prolongation: 40 mg per day
Tagrisso 80 mg tablets	30 per 30 days	60 per 30 days	presengation to mg per day
			Drug interaction, coadministration with a strong CYP3A4 inducer: 160 mg (two 80 mg tablets) per day

<sup>\*</sup>Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

### **III. REFERENCES**

1. Tagrisso [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; August 2018.

Specialty Quantity Limit Tagrisso 2438-H P2019

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

 $\ensuremath{\text{@}}$  2019 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of